Trimodality therapy for bladder conservation in treatment of invasive bladder cancer

Timur Mitin, William U. Shipley, Jason A. Efstathiou, Niall M. Heney, Donald S. Kaufman, Richard J. Lee, Anthony L. Zietman

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

During the past 25 years, prospective clinical trials have established that bladder preservation therapy for select patients with muscle-invasive bladder cancer is a safe and effective alternative to an immediate cystectomy. Cisplatin-based chemoradiation is the most well-studied and accepted component of trimodality therapy; however, other systemic agents have recently been shown effective in combination with radiation therapy, increasing the range of options to allow for better personalization of care. In this review, the most recent advances in the field of bladder-preserving trimodality therapy are presented, and future directions for improving the outcomes are outlined.

Original languageEnglish (US)
Pages (from-to)109-115
Number of pages7
JournalCurrent urology reports
Volume14
Issue number2
DOIs
StatePublished - Apr 1 2013

Keywords

  • Bladder cancer
  • Bladder preservation
  • Cystectomy
  • Muscle invasive
  • Radiation therapy
  • Trimodality therapy

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Trimodality therapy for bladder conservation in treatment of invasive bladder cancer'. Together they form a unique fingerprint.

  • Cite this

    Mitin, T., Shipley, W. U., Efstathiou, J. A., Heney, N. M., Kaufman, D. S., Lee, R. J., & Zietman, A. L. (2013). Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. Current urology reports, 14(2), 109-115. https://doi.org/10.1007/s11934-012-0301-x